Oruka Therapeutics, Inc. (NASDAQ:ORKA) Major Shareholder Buys $1,015,803.36 in Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) major shareholder Venrock Healthcare Capital Par purchased 88,794 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $11.44 per share, for a total transaction of $1,015,803.36. Following the transaction, the insider now owns 4,148,428 shares of the company’s stock, valued at $47,458,016.32. This trade represents a 2.19 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par purchased 8,971 shares of Oruka Therapeutics stock. The shares were acquired at an average cost of $11.86 per share, for a total transaction of $106,396.06.
• On Monday, February 10th, Venrock Healthcare Capital Par purchased 574 shares of Oruka Therapeutics stock. The shares were acquired at an average cost of $10.90 per share, for a total transaction of $6,256.60.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA opened at $10.15 on Friday. Oruka Therapeutics, Inc. has a 12 month low of $9.53 and a 12 month high of $53.88. The business’s 50 day simple moving average is $14.29. The company has a market cap of $355.24 million, a P/E ratio of -1.62 and a beta of 0.77.

Wall Street Analysts Forecast Growth

ORKA has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday, February 7th. Wolfe Research initiated coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $40.00 target price on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $39.86.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $1,037,000. Wellington Management Group LLP bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $2,013,000. Franklin Resources Inc. bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $17,661,000. Point72 Asset Management L.P. bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $11,822,000. Finally, Geode Capital Management LLC bought a new stake in Oruka Therapeutics in the 3rd quarter valued at $343,000. 56.44% of the stock is currently owned by institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.